Acute Concussion and Melatonin
In this study, the investigator plans a randomized trial of melatonin versus placebo post acute pediatric concussion. The investigator hypothesizes that patients with acute concussions managed with melatonin will have improved sleep, decreased depressive symptoms, decreased risk of prolonged concussion symptoms and faster resolution of concussion symptoms.
Conditions:
Concussion, Mild Concussion, Brain Pediatric ALL
Study Start (Actual) 2023-03-01
Primary Completion (Estimated) 2024-06-30
Study Completion (Estimated) 2024-06-30
Enrollment (Estimated) 254
Study Type INTERVENTIONAL
Phase PHASE2
Locations:
📍 Washington, District of Columbia, United States

Eligibility Criteria

Description

    Inclusion Criteria:

    • * Patient diagnosed with an acute concussion within 72 hours
    • * Patient greater than 8 and less than 19 years old

    Exclusion Criteria:

    • * Currently taking psychiatric medication
    • * Cognitive delay
    • * Glasgow Coma Score \< 14
    • * positive findings on head computed tomography
    • * Any patient with intracranial surgery, pathology or instrumentation (e.g. ventriculoperitoneal shunt, brain tumor etc)
    • * Use of melatonin within the last week
Ages Eligible for Study: 12 Years to 18 Years (CHILD, ADULT)
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: Yes

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

  • First Submitted2021-01-20
  • First Submitted that Met QC Criteria2021-01-28
  • First Posted2021-02-01

Study Record Updates

  • Last Update Submitted that Met QC Criteria2024-02-05
  • Last Update Posted2024-02-07
  • Last Verified2024-02